Urogenital Abnormalities in Adenosine Deaminase Deficiency.


Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
05 2020
Historique:
received: 30 11 2019
accepted: 30 03 2020
pubmed: 21 4 2020
medline: 7 8 2021
entrez: 21 4 2020
Statut: ppublish

Résumé

Improved survival in ADA-SCID patients is revealing new aspects of the systemic disorder. Although increasing numbers of reports describe the systemic manifestations of adenosine deaminase deficiency, currently there are no studies in the literature evaluating genital development and pubertal progress in these patients. We collected retrospective data on urogenital system and pubertal development of 86 ADA-SCID patients followed in the period 2000-2017 at the Great Ormond Street Hospital (UK) and 5 centers in Italy. In particular, we recorded clinical history and visits, and routine blood tests and ultrasound scans were performed as part of patients' follow-up. We found a higher frequency of congenital and acquired undescended testes compared with healthy children (congenital, 22% in our sample, 0.5-4% described in healthy children; acquired, 16% in our sample, 1-3% in healthy children), mostly requiring orchidopexy. No urogenital abnormalities were noted in females. Spontaneous pubertal development occurred in the majority of female and male patients with a few cases of precocious or delayed puberty; no patient presented high FSH values. Neither ADA-SCID nor treatment performed (PEG-ADA, BMT, or GT) affected pubertal development or gonadic function. In summary, this report describes a high prevalence of cryptorchidism in a cohort of male ADA-SCID patients which could represent an additional systemic manifestation of ADA-SCID. Considering the impact urogenital and pubertal abnormalities can have on patients' quality of life, we feel it is essential to include urogenital evaluation in ADA-SCID patients to detect any abnormalities, initiate early treatment, and prevent long-term complications.

Sections du résumé

BACKGROUND
Improved survival in ADA-SCID patients is revealing new aspects of the systemic disorder. Although increasing numbers of reports describe the systemic manifestations of adenosine deaminase deficiency, currently there are no studies in the literature evaluating genital development and pubertal progress in these patients.
METHODS
We collected retrospective data on urogenital system and pubertal development of 86 ADA-SCID patients followed in the period 2000-2017 at the Great Ormond Street Hospital (UK) and 5 centers in Italy. In particular, we recorded clinical history and visits, and routine blood tests and ultrasound scans were performed as part of patients' follow-up.
RESULTS AND DISCUSSION
We found a higher frequency of congenital and acquired undescended testes compared with healthy children (congenital, 22% in our sample, 0.5-4% described in healthy children; acquired, 16% in our sample, 1-3% in healthy children), mostly requiring orchidopexy. No urogenital abnormalities were noted in females. Spontaneous pubertal development occurred in the majority of female and male patients with a few cases of precocious or delayed puberty; no patient presented high FSH values. Neither ADA-SCID nor treatment performed (PEG-ADA, BMT, or GT) affected pubertal development or gonadic function.
CONCLUSION
In summary, this report describes a high prevalence of cryptorchidism in a cohort of male ADA-SCID patients which could represent an additional systemic manifestation of ADA-SCID. Considering the impact urogenital and pubertal abnormalities can have on patients' quality of life, we feel it is essential to include urogenital evaluation in ADA-SCID patients to detect any abnormalities, initiate early treatment, and prevent long-term complications.

Identifiants

pubmed: 32307643
doi: 10.1007/s10875-020-00777-8
pii: 10.1007/s10875-020-00777-8
pmc: PMC7253380
doi:

Substances chimiques

Adenosine Deaminase EC 3.5.4.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

610-618

Subventions

Organisme : Department of Health
Pays : United Kingdom

Références

Bone Marrow Transplant. 2017 Jul;52(7):1029-1035
pubmed: 28287638
J Clin Immunol. 2017 Aug;37(6):582-591
pubmed: 28748310
J Clin Immunol. 2017 Oct;37(7):626-637
pubmed: 28842866
Biol Blood Marrow Transplant. 2019 Sep;25(9):1786-1791
pubmed: 31082473
Nat Rev Dis Primers. 2019 May 30;5(1):38
pubmed: 31147553
J Pediatr Urol. 2012 Feb;8(1):2-6
pubmed: 21497555
FASEB J. 2016 Jan;30(1):3-12
pubmed: 26333425
Orphanet J Rare Dis. 2018 Apr 24;13(1):65
pubmed: 29690908
Adv Immunol. 2005;86:1-41
pubmed: 15705418
J Clin Invest. 2008 Apr;118(4):1491-501
pubmed: 18340377
J Allergy Clin Immunol. 2019 Mar;143(3):852-863
pubmed: 30194989
Front Immunol. 2016 Aug 16;7:314
pubmed: 27579027
Front Pediatr. 2019 Sep 24;7:381
pubmed: 31616648
Blood. 2019 Jun 6;133(23):2546-2549
pubmed: 30952673
Curr Opin Pediatr. 2016 Jun;28(3):388-94
pubmed: 27138807

Auteurs

Roberta Pajno (R)

Department of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.

Lucia Pacillo (L)

Department of Pediatrics, "Pietro Barilla" Children Hospital, University of Parma, via Gramsci, 14, Parma, Italy.
Unit of Immune and Infectious Diseases, Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, University Department of Pediatrics (DPUO), Rome, Italy.
Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Salvatore Recupero (S)

Pediatric Immunohematology and Stem Cell Program, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Maria P Cicalese (MP)

Pediatric Immunohematology and Stem Cell Program, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Francesca Ferrua (F)

Pediatric Immunohematology and Stem Cell Program, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Federica Barzaghi (F)

Pediatric Immunohematology and Stem Cell Program, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Silvia Ricci (S)

Division of Pediatric Immunology, Department of Health Sciences, University of Florence and Meyer Children's Hospital, Florence, Italy.

Antonio Marzollo (A)

Pediatric Hematology-Oncology Unit, Department of Women's and Children's Health, University of Padova, Via Giustiniani 3, 35128, Padova, Italy.

Silvia Pecorelli (S)

Department of Pediatric Surgery, Ospedale dei Bambini - Spedali Civili, Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.

Chiara Azzari (C)

Division of Pediatric Immunology, Department of Health Sciences, University of Florence and Meyer Children's Hospital, Florence, Italy.

Andrea Finocchi (A)

Unit of Immune and Infectious Diseases, Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, University Department of Pediatrics (DPUO), Rome, Italy.
Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Caterina Cancrini (C)

Unit of Immune and Infectious Diseases, Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, University Department of Pediatrics (DPUO), Rome, Italy.
Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Gigliola Di Matteo (G)

Unit of Immune and Infectious Diseases, Scientific Institute for Research and Healthcare (IRCCS) Childrens' Hospital Bambino Gesù, University Department of Pediatrics (DPUO), Rome, Italy.
Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

Gianni Russo (G)

Department of Pediatrics, Endocrine Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.

Massimo Alfano (M)

Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Arianna Lesma (A)

Unit of Pediatric Surgery, Department of Urology, IRCCS Ospedale San Raffaele, Milan, Italy.

Andrea Salonia (A)

Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Università Vita-Salute San Raffaele, Milan, Italy.

Stuart Adams (S)

SIHMDS-Haematology, Great Ormond Street Hospital for Children, London, UK.

Claire Booth (C)

Department of Paediatric Immunology, Great Ormond Street Hospital, London, UK.

Alessandro Aiuti (A)

Pediatric Immunohematology and Stem Cell Program, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy. aiuti.alessandro@hsr.it.
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy. aiuti.alessandro@hsr.it.
Università Vita-Salute San Raffaele, Milan, Italy. aiuti.alessandro@hsr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH